tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

CASI Stock Latest News

CASI Pharmaceuticals Secures China Drug Registration for Thiotepa Ahead of Planned Asset Disposal
Company AnnouncementsCASI Pharmaceuticals Secures China Drug Registration for Thiotepa Ahead of Planned Asset Disposal
8d ago
6K
CASI
CASI Pharmaceuticals Fails to Renew FOLOTYN Import License in China, Halts Sales
PremiumCompany Announcements
CASI Pharmaceuticals Fails to Renew FOLOTYN Import License in China, Halts Sales
27d ago
6K
CASI
Casi Pharmaceuticals announces NMPA approval of CTA for Phase 1/2 CID-103 study
PremiumThe Fly
Casi Pharmaceuticals announces NMPA approval of CTA for Phase 1/2 CID-103 study
1M ago
CASI
CASI Pharmaceuticals Closes Second Tranche of US$20 Million Convertible Note Financing
PremiumCompany Announcements
CASI Pharmaceuticals Closes Second Tranche of US$20 Million Convertible Note Financing
1M ago
6K
CASI
Casi Pharmaceuticals announces results from Phase 1 study of CID-103
PremiumThe Fly
Casi Pharmaceuticals announces results from Phase 1 study of CID-103
1M ago
CASI
CASI Pharmaceuticals Closes First US$5 Million Tranche of Convertible Note Financing
PremiumCompany AnnouncementsCASI Pharmaceuticals Closes First US$5 Million Tranche of Convertible Note Financing
2M ago
6K
CASI
CASI Pharmaceuticals Wins Nasdaq Listing Extension to February 2026
Premium
Company Announcements
CASI Pharmaceuticals Wins Nasdaq Listing Extension to February 2026
2M ago
6K
CASI
CASI Pharmaceuticals Secures $20 Million for Renal AMR Study
Premium
Company Announcements
CASI Pharmaceuticals Secures $20 Million for Renal AMR Study
2M ago
6K
CASI
Casi Pharmaceuticals enters into $20M convertible note financing
PremiumThe Fly
Casi Pharmaceuticals enters into $20M convertible note financing
2M ago
CASI
Buy Rating for CASI Pharmaceuticals: Promising CID-103 Clinical Data and Competitive Positioning
PremiumRatings
Buy Rating for CASI Pharmaceuticals: Promising CID-103 Clinical Data and Competitive Positioning
2M ago
CASI
Casi Pharmaceuticals announces CID-103 immune thrombocytopenia study results
PremiumThe Fly
Casi Pharmaceuticals announces CID-103 immune thrombocytopenia study results
2M ago
CASI
CASI Pharmaceuticals Appoints James Huang as Non-Executive Chairman
PremiumCompany Announcements
CASI Pharmaceuticals Appoints James Huang as Non-Executive Chairman
3M ago
6K
CASI
Casi Pharmaceuticals appoints James Huang as non-executive chairman
PremiumThe FlyCasi Pharmaceuticals appoints James Huang as non-executive chairman
3M ago
CASI
CASI Pharmaceuticals Reports Q3 2025 Results Amid Nasdaq Delisting Appeal
Premium
Company Announcements
CASI Pharmaceuticals Reports Q3 2025 Results Amid Nasdaq Delisting Appeal
3M ago
6K
CASI
CASI Pharmaceuticals Appeals Nasdaq Delisting Determination
Premium
Company Announcements
CASI Pharmaceuticals Appeals Nasdaq Delisting Determination
3M ago
6K
CASI
CASI Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
CASI Earnings Report this Week: Is It a Buy, Ahead of Earnings?
3M ago
CASI
CASI Pharmaceuticals Advances CID-103 in Promising ITP Study
PremiumCompany Announcements
CASI Pharmaceuticals Advances CID-103 in Promising ITP Study
4M ago
CASI
Casi Pharmaceuticals appoints James Hunag to board of directors
PremiumThe Fly
Casi Pharmaceuticals appoints James Hunag to board of directors
5M ago
CASI
CASI Pharmaceuticals Strengthens Board with Industry Veteran James Huang
PremiumCompany Announcements
CASI Pharmaceuticals Strengthens Board with Industry Veteran James Huang
5M ago
6K
CASI
CASI announces SMC recommendation to escalate CID-103 dose to next cohort
PremiumThe FlyCASI announces SMC recommendation to escalate CID-103 dose to next cohort
5M ago
CASI
CASI Pharmaceuticals: Strategic Advancements and Leadership Strengthening Drive Buy Rating with $4.00 Price Target
Premium
Ratings
CASI Pharmaceuticals: Strategic Advancements and Leadership Strengthening Drive Buy Rating with $4.00 Price Target
6M ago
CASI
CASI Pharmaceuticals Strengthens Board with New Appointment
Premium
Company Announcements
CASI Pharmaceuticals Strengthens Board with New Appointment
6M ago
6K
CASI

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >